12 July 2024 : Clinical Research
Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center
Zhuan'e Yao ABCDEFG 1,2, Pengbo Wang ABCDE 1, Qinjuan Fu BD 1, Qiong Song BC 1, Ai Liu DF 1, Huan Li BCD 1, Wei Wang DF 1, Peng Zhang ACDEF 2*DOI: 10.12659/MSM.943529
Med Sci Monit 2024; 30:e943529
Table 3 Comparisons of the SF-36 score in patients before and after sacubitril/valsartan treatment.
| Variable | Before sacubitril/valsartan | After sacubitril/valsartan | P-value |
|---|---|---|---|
| Physical functioning | 45 (30–65) | 67.50 (60–73.75) | 0.003 |
| Role physical | 50 (25–50) | 75 (50–75) | <0.001 |
| Bodily pain | 41 (30.63–51) | 50 (40–74) | 0.063 |
| General health | 20 (20–32) | 46 (32–47) | <0.001 |
| Vitality | 25 (20–35) | 40 (25–43.75) | 0.005 |
| Social functioning | 37.5 (25–63.75) | 62.5 (37.5–75) | 0.001 |
| Role emotional | 33.3 (33.3–66.6) | 66.6 (33.3–100) | 0.007 |
| Mental health | 40 (32–44) | 44 (33–56) | 0.028 |
| Physical Component Summary | 40.00±6.41 | 56.20±9.86 | <0.001 |
| Mental Component Summary | 39.99±6.14 | 52.59±11.00 | <0.001 |